Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Evotec SE

Evotec SE (EVO) Stock Overview

Explore Evotec SE’s financial performance, market position, analyst ratings, and future outlook.

EVO●NASDAQ
HealthcareDrug Manufacturers - Specialty & Generic
$2.003
$0.10(4.60%)
U.S. Market is Open · 14:50

Evotec SE (EVO)

Meyka AI Score

Z

Key Financials

Market Cap778M
P/E Ratio-3.46
EPS (TTM)$-0.71
ROE-0.24%
Fundamental Analysis

AI Price Forecasts

1 Month$1.57
3 Months$1.99
1 Year Target$3.11

EVO Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Evotec SE (NASDAQ: EVO) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Evotec SE's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of EVO on the NASDAQ shows an RSI of 52.79, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $3.11 for the NASDAQ listing.

Key metrics behind Evotec SE's NASDAQ-traded stock include a P/E ratio of -3.46 and a market capitalization of 778M. Combined with our AI analysis, these give both institutional and retail investors a clear view of EVO on the NASDAQ.

Price Performance (NASDAQ: EVO)

1-Day Change
4.29%
5-Day Change
10.05%
1-Month Change
-21.51%
3-Month Change
-27.00%
6-Month Change
-36.15%
Year-to-Date (YTD) Change
-28.90%
1-Year Change
-42.52%
3-Year Change
-81.52%
5-Year Change
-90.70%
All-Time (Max) Change
112.62%

Contact Information

https://www.evotec.com
49 40 560 81 0
Essener Bogen 7, Hamburg, HA, 22419

Company Facts

45,530 Employees
IPO DateFeb 5, 2004
CountryDE
Actively Trading

Frequently Asked Questions